Literature DB >> 22977393

Drugs for pulmonary arterial hypertension: a systematic review of the clinical-effectiveness of combination therapy.

.   

Abstract

Entities:  

Year:  2010        PMID: 22977393      PMCID: PMC3411136     

Source DB:  PubMed          Journal:  CADTH Technol Overv        ISSN: 1203-9012


× No keyword cloud information.
  9 in total

1.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Authors:  M Humbert; R J Barst; I M Robbins; R N Channick; N Galiè; A Boonstra; L J Rubin; E M Horn; A Manes; G Simonneau
Journal:  Eur Respir J       Date:  2004-09       Impact factor: 16.671

2.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; Ronald J Oudiz; Adaani Frost; Victor F Tapson; Srinivas Murali; Richard N Channick; David B Badesch; Robyn J Barst; Henry H Hsu; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2006-08-31       Impact factor: 21.405

3.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Authors:  Nazzareno Galiè; Adam Torbicki; Robyn Barst; Philippe Dartevelle; Sheila Haworth; Tim Higenbottam; Horst Olschewski; Andrew Peacock; Giuseppe Pietra; Lewis J Rubin; Gerald Simonneau; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin Cowie; Verconcia Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; Keith McGregor; João Morais; Ali Oto; Otto A Smiseth; Joan Albert Barbera; Simon Gibbs; Marius Hoeper; Marc Humbert; Robert Naeije; Joanna Pepke-Zaba
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

4.  Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland.

Authors: 
Journal:  Thorax       Date:  2008-03       Impact factor: 9.139

5.  Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

Authors:  David B Badesch; Steven H Abman; Gerald Simonneau; Lewis J Rubin; Vallerie V McLaughlin
Journal:  Chest       Date:  2007-06       Impact factor: 9.410

6.  First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

Authors:  K Lunze; N Gilbert; S Mebus; O Miera; W Fehske; F Uhlemann; E G Mühler; P Ewert; P E Lange; F Berger; I Schulze-Neick
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

7.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

Review 8.  Pulmonary arterial hypertension.

Authors:  Kelly M Chin; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2008-04-22       Impact factor: 24.094

9.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Authors:  Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch
Journal:  Ann Intern Med       Date:  2008-10-21       Impact factor: 25.391

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.